Herein, we highlight that tumor‐intrinsic SETD2 deficiency reshapes the immunosuppressive TME via neutrophils in pancreatic tumorigenesis, potentially providing a therapeutic strategy for pancreatic cancer patients with SETD2 deficiency. The gene discussed is SETD2; the disease is neoplasm.